Network-based analysis of calcium-binding protein genes identifies Grp94 as a target in human oral carcinogenesis

H Nomura¹, K Uzawa¹, Y Yamano¹, K Fushimi¹, T Ishigami¹, Y Kato¹, K Saito¹, D Nakashima¹, M Higo¹, Y Kouzu¹, K Ono¹, K Ogawara¹, M Shiiba¹, H Bukawa², H Yokoe² and H Tanzawa¹,²,³

¹Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, 1-8-1Inohana, Chuo-ku, Chiba 260-8670, Japan; ²Division of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, 1-8-1Inohana, Chuo-ku, Chiba 260-8670, Japan; ³Center of Excellence (COE) Program in the 21st Century, Graduate School of Medicine, Chiba University, 1-8-1Inohana, Chuo-ku, Chiba 260-8670, Japan

To characterise Ca²⁺-binding protein gene expression changes in oral squamous cell carcinomas (OSCCs), we compared the gene expression profiles in OSCC-derived cell lines with normal oral tissues. One hundred Ca²⁺-binding protein genes differentially expressed in OSCCs were identified, and genetic pathways associated with expression changes were generated. Among genes mapped to the network with the highest significance, glucose-regulated protein 94 kDa (Grp94) was evaluated further for mRNA and protein expression in the OSCC cell lines, primary OSCCs, and oral premalignant lesions (OPLs). A significant (P<0.001) overexpression of Grp94 protein was observed in all cell lines compared to normal oral epithelium. Immunohistochemical analysis showed highly expressed Grp94 in primary OSCCs and OPLs, whereas most of the corresponding normal tissues had no protein immunoreaction. Real-time quantitative reverse transcriptase-PCR data agreed with the protein expression status. Moreover, overexpression of Grp94 in primary tumours was significantly (P<0.001) correlated with poor disease-free survival. The results suggested that Grp94 may have potential clinical application as a novel diagnosis and prognostic biomarker for human OSCCs.

Keywords: oral squamous cell carcinoma; Ca²⁺-binding protein; pathway analysis; glucose-regulated protein 94 kDa; poor prognosis

Cytosolic Ca²⁺, a basic parameter of intracellular homeostasis, has a wide variety of important cellular functions, that is, cell growth and proliferation, processing and folding of endoplasmic reticulum (ER)-translated proteins, and Ca²⁺-mediated signalling in response to extracellular stimuli (Berridge, 2006). Under physiologic conditions, many aspects of these processes are mediated by members of the Ca²⁺-binding protein (Nelson and Chazin, 1998). Since considerable evidence shows that intracellular Ca²⁺ deregulation is crucial for tumour growth and development (Durham and Walton, 1982; Huang et al, 2005; Ding et al, 2006; Thebault et al, 2006), understanding the genetic mechanisms of the Ca²⁺-binding protein genes involved in carcinogenesis is imperative for the development of new therapeutic strategies.

Ca²⁺-binding protein is characterised by the presence of the putative Ca²⁺-binding domain; EF-hand structure is an essential mediator of intracellular Ca²⁺ control elements, such as the plasma membrane Ca²⁺ pumps or ER (Koch et al, 1986; Nelson and Chazin, 1998; Haeseler et al, 2000). A number of Ca²⁺-binding proteins are thought to be implicated in establishing the malignant and metastatic phenotypes of various tumours (Chen et al, 1997; Takenaga et al, 1997; Van Ginkel et al, 1998), and recent studies have reported altered expression of several Ca²⁺-binding protein genes in a wide range of human malignancies (Bustin et al, 2001; Pietas et al, 2002; Lakshminikuttayamma et al, 2004; Imazawa et al, 2005). Regarding oral squamous cell carcinomas (OSCCs), aberrant expression of S100 Ca²⁺-binding protein families seen in tumour sites has been correlated with cancer cell invasion or metastasis (Moriyama-Kita et al, 2004; Tsai et al, 2005). We recently identified certain Ca²⁺-binding protein genes differentially expressed in OSCCs compared with normal oral squamous epithelium, including PMCA1 (Saito et al, 2006), ITPKA (Kato et al, 2006), ATP2A2 (Endo et al, 2004), CALR (Shimada et al, 2005), and E-cadherin (Saito et al, 1998).

We recently developed the strategy of using a knowledge-based network approach to search for candidate genes relevant to the treatment of oral cancers (Kasamatsu et al, 2005; Higo et al, 2006; Ishigami et al, 2007). Thus, this study aimed to explore further the global changes in Ca²⁺-binding protein genes associated with OSCCs by applying network development tools to expand on microarray analysis methods. In addition, a candidate gene for therapeutic targeting and follow-up studies was evaluated further for the expression status of the mRNA and protein in a large series of OSCCs and oral premalignant lesions (OPLs).

MATERIALS AND METHODS

Tissue specimens

Eighty pairs of primary OSCC samples and corresponding normal oral epithelial tissues or 20 OPLs (diagnosed as oral leukoplakias) were obtained at the time of surgery performed at Chiba University Hospital between 1998 and 2005. All patients provided informed consent.
consent according to the protocol that was reviewed and approved by the Institutional Review Board of Chiba University before any procedures were performed. Postoperative follow-up data were collected until April 2006 or until the day of the patient's death, metastasis, or local recurrence. The median follow-up time was 2.1 years (range: 3 months to 8 years).

The resected tissues were divided into two parts: one was frozen immediately after removal of the surrounding normal tissue and stored at −80°C until RNA extraction, and another was fixed in 10% buffered formaldehyde solution for pathologic diagnosis and immunohistochemical staining. Histopathologic diagnosis of each tumour specimen was performed according to the International Histological Classification of Tumours by the Department of Pathology, Chiba University Hospital. Clinicopathologic staging was determined by the TNM classification of the International Union against Cancer. All OSCC samples were histologically confirmed and checked to ensure the presence of tumour in greater than 80% of specimens.

Formalin-fixed, paraffin-embedded human breast cancer tissue (positive control for Grp94 expression) was purchased from Lab Vision Co., Fremont, CA, USA (GRP94, Ab-1, positive control for immunohistochemistry).

Cell culture

The OSCC-derived cell lines used in this study were HSC-2, HSC-3, CaO-22 (Human Science Research Resources Bank, Osaka, Japan), HaCaT (provided by Dr Fujita, Wakayama Medical University, Wakayama, Japan), and OK-92 (established from carcinoma of the tongue in our department) (Takahashi et al., 1989). All OSCC-derived cell lines were cultured in Dulbecco’s modified Eagle’s medium F-12 HAM (Sigma-Aldrich Co., St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (Sigma) and 50 U ml⁻¹ penicillin and streptomycin (Sigma). The human normal oral keratinocytes (HNOKs) cell line was cultured and maintained in defined keratinocyte-SFM (Gibco BRL, Gaithusberg, Germany). All cell lines were incubated at 37°C in a humidified atmosphere with 5% CO₂.

Protein and mRNA extraction

Protein was extracted when the cells reached 80–90% confluence; they were washed two times with phosphate-buffered saline (PBS), scraped into a tube, and centrifuged briefly. The cell pellets were incubated for 30 min in a lysis buffer (LB) containing 7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris pH 8.0, and lysed by sonication (3 x 10 s pulses on ice). The sample was centrifuged at 13 000 r.p.m. for 20 min. The supernatant containing the cell proteins then was recovered and the protein concentration was measured with a Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA) and adjusted to 1 mg ml⁻¹ with LB. The pH of the protein sample was adjusted to 8.5 with 30 mM Tris–HCl. Total RNA was extracted using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. Total protein extracted from a human breast cancer cell line, SKBR3 (positive control for Grp94 expression), was obtained from Lab Vision (GRP94, Ab-1, positive control for Western blotting). Each extracted RNA or protein was stored separately at −80°C until use.

Affymetrix GeneChip hybridisation

Double-stranded cDNA was synthesised from 20 μg of total RNA using the Superscript Choice system (Invitrogen). After phenol/chloroform extraction and ethanol precipitation, a biotin-labelled in vitro transcription reaction was carried out using the cDNA template (Enzo Bioarray, Farmingdale, NY, USA). cRNA (7 μg) was fragmented according to Affymetrix protocols and added to the recommended hybridisation mixture. Expression profiles were created using the Human Genome U 133 Plus 2.0 arrays containing 54 675 probe sets (Affymetrix, Santa Clara, CA, USA). Arrays were stained with phycoerythrin–streptavidin, and the signal intensity was amplified by treatment with a biotin-conjugated anti-streptavidin antibody followed by a second staining with phycoerythrin–streptavidin. Arrays stained a second time were scanned using the Affymetrix GeneChip Scanner 3000 (Affymetrix). Expression data were analysed using GeneChip Operating Software 1.1 (Affymetrix), and Ca²⁺-binding protein genes were then classified by GeneSpring 6.1 (Silicon Genetics, Redwood City, CA, USA).

Network and gene ontology analysis

A list of Ca²⁺-binding protein genes identified by microarray analysis was used for network and gene ontology analyses. Gene accession numbers were imported into the Ingenuity Pathway Analysis (IPA) Software (Ingenuity Systems, Mountain View, CA, USA). The IPA database consists of proprietary ontology representing 300 000 biologic objects ranging from genes, proteins, and molecular and cellular processes. More than 11 200 human genes are currently represented in the database. The genes were categorised based on location, cellular components, and reported or suggested biochemical, biologic, and molecular functions using the software. The identified genes also were mapped to genetic networks available in the Ingenuity database and then ranked by score. The score is the probability that a collection of genes equal or greater than the number in a network could be achieved by chance alone. A score of 3 indicates a 1/1000 chance that the focus genes are in a network due to random chance. Therefore, a score of 3 or higher has a 99.9% confidence level of not being generated by random chance alone. This score was used as the cutoff for identifying gene networks.

Western blot analysis

Among genes identified, glucose-regulated protein 94 kDa (Grp94) was selected for further analyses. We carried out Western blot analysis to investigate Grp94 protein expression in normal oral epithelium and OSCC-derived cell lines. Protein extracts were electrophoresed on 11% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels, transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA), and blocked for 1 h at room temperature in 5% skim milk. Immunoblot PVDF membranes were washed with 0.1% Tween-20 in TBS (TBS-T) five times, and 2 μg ml⁻¹ affinity-purified rat anti-human Grp94 monoclonal antibody (Lab Vision) was added directly to the TBS-T solution for 2 h at room temperature. The PVDF membranes were washed again and incubated with 1:10 000 ratio of horseradish peroxidase (HRP)-conjugated antirat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a secondary antibody for 20 min at room temperature. The membranes were then incubated with enhanced chemiluminescence (ECL) + HRP substrate solution included in the ECL + kit (Amersham Biosciences, Buckinghamshire, UK), and immunoblotting was visualised by exposing the membrane to Hyperfilm (Amersham Biosciences). Triplicate examinations were performed to confirm the specificity of the antibody.

Immunofluorescence

The cells grown on glass coverslips were washed with PBS, fixed in 4% paraformaldehyde for 10 min at 37°C followed by absolute methanol for 10 min at 4°C, and blocked in PBS containing 1% skimmed milk for 10 min. The samples then were incubated with anti-Grp94 antibody (Lab Vision) at a dilution of 1:100 for 2 h, rinsed two times with PBS, and incubated with goat antirat
secondary antibody labelled with Alexa Fluor 546 (Molecular Probes, Leiden, The Netherlands) for 1 h. For counterstaining of the nucleus, the dishes were then incubated with 1 μg ml⁻¹ Cellstain-DAP1 (Dojindo Laboratories, Kumamoto, Japan) in PBS for 10 min. The samples were observed under a Leica TCS2-MP confocal system (Leica Laserteknik, Mannheim, Germany) and Coherent Mira tunable pulsed titanium sapphire laser (Coherent Laser Group, Santa Clara, CA, USA).

Table 1  Genetic networks in the OSCC-derived cell lines

| Network | Genes in ingenuity networks | Function | Score |
|---------|-------------------------------|----------|-------|
| 1       | ATGR1, BDKRB2, CACNA1B, CACNA1C, CACNA1S, CACNB1, CACNG1, CAPN3, CAPN9, CCL2, CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCR1, CCR5, CSPG2, CXCL12, DSG2, EGF, EPS15, F10, MYL2, NOS2A, PLA2G10, PLA2G2A, PLCD1, PLEK, PRKCA, RASGRF3, RYR1, TGMI, Grp94 | Cell signalling, cellular function, and maintenance | 71 |
| 2       | ACT1, ANXA1, ATPI, CALM3, CDH11, COP55, DIABLO, DGS3, FGFI10, FPR1, IL1B, IR1RN, INHBA, LTB2, MGP, MMP9, MPP13, MTPN, NOTCH4, PCDH7, RXRA, S100A7, S100A8, S100A9, SAA1, SCARB1, SCUBE1, SCUBE9, SERPINA3, SOD1, TNF, TNFRSF4, TNFRSF9, TPO, UMOD | Lipid metabolism, molecular transport | 20 |
| 3       | ACT1, ATPIA3, BAG3, BBC3, BCL2, CALU1, CCL9, CCR7, CDS1, CHGB, CHHRP, CIB1, CK2, CLEC3B, CD24, CGH, CNTNAP1, CTYR, CXCR4, CYB, CYBRD2, CYLD, DAB2, DDX5, DMP1, DROSHA, DSG2, DUSP2, E2F1, EGR1, EGR2, EGR4, EGFR, EGF, ETV5, ITF1, JUP, KDM5A, LOG2, LRP1B, MIG-6, MYL1, PPP1R3A, PRKCSH, RALGDS, RASGRF1, RB1, ROCK1, RPS6KB2, RRM1, RRM2, SLC32A1, SLC9A1, TERT | Cancer, cell morphology, cellular compromise | 20 |
| 4       | AHNAK, ATPIA2, BBC3, BGN, BNP, CANX, CCR6, CDKN1B, CHGA, CHRD, CILSA1, CTSD, CUBN, DDX5, DMP1, DSN1, DRG2, DUSP2, E2F1, EGR1, EGR2, EGR4, EGFR, EGF, ETV5, ITF1, JUP, KDM5A, LOG2, LRP1B, MIG-6, MYL1, PPP1R3A, PRKCSH, RALGDS, RASGRF1, RB1, ROCK1, RPS6KB2, RRM1, RRM2, SLC32A1, SLC9A1, TERT | DNA replication, recombination, and developmental disorder, carbohydrate metabolism, Cardiovascular system | 17 |
| 5       | ACT2, ACTN3, CALM1, CASQ1, CD47, CDK6, CDKN1A, CTSK, CXCL12, DCCN, ERBB2, ERBB3, ERBB4, ERG, EPHB2, FBLN2, FN1, GHR, GRB7, GRK1, HAS2, HBEGF, HRC, IFNA2, IL6, MTPN, MYL9, MYOZ1, PIGF, RCV1, S100A4, SERPINA3, TGM1, TIMP3, TNC, TRDN | Cell movement, proliferation, cellular migration, cell death | 17 |

*Genes in boldface were identified by microarray analysis to be expressed differentially more than two-fold in OSCCs. Other genes were either not on the expression array or not significantly regulated. **A score > 3 was considered significant.

Figure 1  Network with the highest score (network 1). Expression levels of all 35 genes (100%) are altered significantly in the oral squamous cell carcinomas (OSCCs). Functional relationships between gene products based on known interactions in ingenuity pathway analysis (IPA) knowledge are described.
by 30-min incubation in a mixture of 0.3% hydrogen peroxide solution in 100% methanol. After being washed with PBS buffer, sections were then incubated with primary antibody anti-Grp94 antibody (1:100 dilution) at room temperature in a moist chamber for 2 h. After being washed with PBS buffer, the slides were treated with biotinylated secondary antibody for 1 h followed by colour development in 3,3’-diaminobenzidine tetrahydrochloride (Dako Japan Inc., Kyoto, Japan). Finally, the slides were lightly counterstained with haematoxylin. A known positive breast cancer control section for Grp94 was clearly stained. While the breast cancer cells were immunohistochemically positive for Grp94, those of the negative control prepared by omitting the primary antibody were negative, thus confirming the staining specificity. To quantitate the state of the Grp94 protein expression, the mean percentage of positive tumour cells was determined in at least five random fields at ×400 magnification in each section. The intensity of the Grp94 immunoreaction was scored as follows: 1+; weak; 2+; moderate; and 3+, intense. The percentage of positive tumour cells and the staining intensity were then multiplied to produce a Grp94-immunohistochemical staining score. Cases with a Grp94-immunohistochemical staining score exceeding 65.56 (maximum score of normal tissues) were considered positive. Two independent pathologists, neither of whom had knowledge of the patients’ clinical status, made these judgments.

mRNA expression analysis

The expression levels of Grp94 mRNA were examined in 50 OSCC specimens from patients with primary tumours among the OSCC cases studied by immunohistochemical staining. Control reactions were prepared in parallel without reverse transcriptase (RT). Before cDNA synthesis, residual genomic DNA was removed from the total RNA using DNase I treatment (DNA-free; Ambion, Austin, TX, USA). The primer sequences used to analyse Grp94 mRNA expression were 5’-AGCAAGAGGTGTGGATC-3’ (nucleotides 1392–1410) and 5’-CCTCAATTTTGTCAGGGTG-3’ (nucleotides 1607–1626). The sequences of specific primers were checked before use to avoid amplification of genomic DNA or pseudogenes by the Primer3 program (available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Amplified products were analysed by 3% agarose gel electrophoresis to ascertain size and purity. Real-time quantitative RT (qRT)–PCR

Table 2

| Affymetrix no. | Gene | Molecular function | Location | Fold changea |
|---------------|------|--------------------|----------|--------------|
| 217901_s_at   | DSG2 | Cell adhesion      | Plasma membrane | 85.187       |
| 200599_s_at   | Grp94| Protein folding and sorting, antigen presentation | Plasma membrane | 5.479       |
| 210037_s_at   | NOS2A| Nitric oxide synthase activity | Cytoplasm | 5.072       |
| 1560074_s_at | PRKCA| Protein kinase C activity | Cytoplasm | 3.781       |
| 21061_s_at    | CAPN9| Calpain activity | Unknown | 3.003       |
| 207162_s_at   | CACNA1B| Voltage-gated calcium channel activity | Plasma membrane | 2.894       |
| 207222_s_at   | PLA2G10| Unknown | Extraglacial space | 2.749       |
| 207225_s_at   | EPS15| Protein binding | Plasma membrane | 0.4539      |
| 201511_s_at   | BDKRB2| Receptor activity | Plasma membrane | 0.4464      |
| 205434_s_at   | CACNA1C| Voltage-gated calcium channel activity | Plasma membrane | 0.4288      |
| 218075_s_at   | AGTR1| Receptor activity | Plasma membrane | 0.3305      |
| 1535840_s_at | CCR1| Chemokine receptor activity | Plasma membrane | 0.2580      |
| 207798_s_at   | CACNB1| Voltage-gated calcium channel activity | Plasma membrane | 0.2346      |
| 228767_s_at   | CCL13| Chemokine receptor activity | Extracellular space | 0.2200      |
| 235070_s_at   | PLEK| Reorganisation | Cytoplasm | 0.1697      |
| 229819_s_at   | CCR5| Chemokine receptor activity | Plasma membrane | 0.1640      |
| 228376_s_at   | CCL7| Chemokine receptor activity | Extracellular space | 0.1611      |
| 218529_s_at   | F10| Peptidase activity | Extracellular space | 0.1583      |
| 224938_s_at   | PLA2G2A| Protein binding | Extracellular space | 0.1339      |
| 224939_s_at   | CACNA15| Voltage-gated calcium channel activity | Plasma membrane | 0.1256      |
| 214711_s_at   | CCL5| Chemokine receptor activity | Extracellular space | 0.1172      |
| 214319_s_at   | CCL3| Chemokine receptor activity | Extracellular space | 0.1071      |
| 1555904_s_at | CCL15| Chemokine receptor activity | Extracellular space | 0.0868      |
| 209665_s_at   | RASGRP3| Protein binding | Cytoplasm | 0.0810      |
| 220781_s_at   | CACNG1| Voltage-gated calcium channel activity | Plasma membrane | 0.0744      |
| 1553086_s_at | CSPG2| Unknown | Extracellular space | 0.0736      |
| 212698_s_at   | EGF| Protein binding | Extracellular space | 0.0611      |
| 226627_s_at   | PLCD1| Unknown | Cytoplasm | 0.0381      |
| 213666_s_at   | CXCL12| Chemokine receptor activity | Extracellular space | 0.0350      |
| 211990_s_at   | CAPN3| Calpain activity | Cytoplasm | 0.0227      |
| 216598_s_at   | CCL2| Chemokine receptor activity | Extracellular space | 0.0198      |
| 235340_s_at   | CCL14| Chemokine receptor activity | Extracellular space | 0.0165      |
| 205485_s_at   | RYR1| Voltage-gated calcium channel activity | Plasma membrane | 0.0126      |
| 206008_s_at   | TGM1| Cell formation | Plasma membrane | 0.0109      |
| 209742_s_at   | MYL2| Motor activity | Cytoplasm | 0.0100      |

AGTR1 = angiotensin II receptor, type 1; BDKRB2 = bradykinin receptor B2; CACNA1B = calcium channel, voltage-dependent, L type, α1B- subunit; CACNA1C = calcium channel, voltage-dependent, L type, α1C subunit; CACNB1 = calcium channel, voltage-dependent, β1 subunit; CACNG1 = calcium channel, voltage-dependent, γ subunit 1; CAPN3 = calpain 3 (p94); CAPN9 = calpain 9; CCL2 = chemokine (C-C motif) ligand 2; CCL3 = chemokine (C-C motif) ligand 3; CCL5 = chemokine (C-C motif) ligand 5; CCL7 = chemokine (C-C motif) ligand 7; CCL13 = chemokine (C-C motif) ligand 13; CCL14 = chemokine (C-C motif) ligand 14; CCR1 = chemokine (C-C motif) receptor 1; CCR5 = chemokine (C-C motif) receptor 5; CCR2 = chemokine (C-C motif) receptor 2; CXCL12 = chemokine (C-X-C motif) ligand 12; DSG2 = desmoglein 2; EGF = epidermal growth factor; EPS15 = epidermal growth factor receptor pathway substrate 15; F10 = coagulation factor X; Grp94 = glucose regulated protein, 94 kDa; H2A: histone H2A; MLT2 = myostatin, light polypeptide 2, regulatory, cardiac, slow; NOS2A = nitric oxide synthase 2A; PLA2G2A = phospholipase A2, group IIA; PLA2G10 = phospholipase A2, group X; PLCD1 = phospholipase C, delta 1; PLEK = pleckstrin; PRKCA = protein kinase C, α; RASGRF3 = Ras guanyl releasing protein 3; RYR1 = ryanodine receptor 1; TGM1 = transglutaminase 1. Fold overexpression for microarray data of OSCC-derived cell lines compared to normal control.
was performed with a single method using the LightCycler FastStart DNA Master SYBR Green I kit (Roche, Mannheim, Germany). To prepare the standard curve, 3 μg of total RNA from normal oral tissue was reverse-transcribed with Superscript RT (Life Technologies, Grand Island, NY, USA) and oligo(dT)12-18 primer, after which serial dilutions were made corresponding to cDNA transcribed from 300, 30, 3.0, and 0.3 ng of total RNA. PCRs using LightCycler apparatus were carried out in a final volume of 20 μl of reaction mixture consisting of 2 μl of FirstStart DNA Master SYBR Green I mix, 3 mM MgCl2, and 0.2 μl of primers, according to the manufacturer's instructions. The reaction mixture then was loaded into glass capillary tubes and submitted to an initial denaturation at 95°C for 10 min, followed by 45 rounds of amplification at 95°C (10 s) for denaturation, 58°C (10 s) for annealing and 72°C for extension, with a temperature slope of 20°C-s⁻¹, performed in the LightCycler. The transcript amount for Grp94 was estimated from the respective standard curves and normalised to the GAPDH transcript amount determined in corresponding samples.

Statistical analysis

Differences in gene expression levels between Grp94-positive and Grp94-negative cases were calculated with the Mann–Whitney's U-test. Correlations between Grp94-immunohistochemical staining scores and clinicopathologic features were evaluated by Fisher's exact test. Overall survival time was defined as the interval between the date of treatment and the date of death or until the last objective follow-up information was obtained. Disease-free survival time was regarded as the time interval between tumour treatment and detection of the first locoregional recurrence, distant metastasis, or both or the date of the last follow-up, whichever occurred first. Patients without evidence of disease (local recurrence or metastasis) during follow-up were considered to have a good prognosis; patients with local recurrence, distant metastasis during follow-up were regarded as having a poor prognosis. Survival curves were obtained by the Kaplan–Meier method and differences in survival rates between Grp94-positive and Grp94-negative cases were compared by log-rank tests with 95% significance. The criterion for statistical significance was P < 0.05. The data are expressed as the mean values ± s.e.

RESULTS

Altered Ca²⁺-binding protein genes expression in OSCC-derived cell lines

To investigate the expression profile changes of Ca²⁺-binding protein genes in OSCC, we initially performed oligonucleotide microarray analyses using the Affymetrix U133A chips, which contained 54,675 probe sets with RNAs isolated from four OSCC-derived cell lines (HSC-2, HSC-3, H-1, and Sa-3). Control RNAs consisted of a pool made of normal tongue tissue RNAs extracted from three patients. Expression data were analysed using the GeneChip Operating Software 1.1 (Affymetrix) and GeneSpring 6.1 (Silicon Genetics). Of the 2241 Ca²⁺-binding protein gene transcripts analysed, 100 (4.4%) were identified as genes that were differentially expressed at least two-fold in all OSCC-derived cell lines examined compared with controls. Of these, 24 genes were found to be upregulated and 76 genes were downregulated in OSCC (data not shown).

Network and gene ontology analysis

On the basis of all genes identified as described previously (referred to as focus genes), new and expanded pathway maps and connections and specific gene–gene interactions were inferred, functionally analysed, and used to build on the existing pathway using the IPA knowledge base. To generate networks, the knowledge base was queried for interactions between focus genes and all other gene objects stored in the database. Six networks were found to be significant in OSCC in that they had more of the identified genes present than would be expected by chance (Table 1). Of them, the network with the highest score (network 1, score = 71) was generated with all focus genes (Figure 1; Table 2). We also performed gene ontology analyses of 100 focus genes using the IPA tool. Seventy-six upregulated genes were associated with cancer-related functions, cell death, and the cell cycle; 24 downregulated genes were associated with cellular movement, signalling, and function and maintenance (Table 3). In particular, we found that the cellular signalling was contained in both the upregulated and downregulated groups. Six upregulated genes were associated with a variety of cellular signalling functions, including induction/production of nitric oxide, inhibition of cyclic adenosine monophosphate, and inactivation of mitogen-activated protein kinase. In contrast, 31 downregulated groups played a critical role in cellular signalling, which is related

### Table 3 Functional characterisation of Ca²⁺-binding protein genes altered expressed in OSCC-derived cell lines

| Relevant function and disease | P-value | Gene, no a |
|-------------------------------|---------|------------|
| Top-10 functions associated with upregulated genes in OSCC-derived cell lines |         |            |
| Cancer b                      | 1.15E-3 | 7          |
| Cell death                    | 4.27E-2 | 4          |
| Cell cycle                    | 6.42E-2 | 6          |
| Cell-to-cell signalling and interaction | 1.86E-3 to 6 |
| Small molecule biochemistry   | 6.95E-2 | 2          |
| Molecular transport           | 6.42E-2 | 3          |
| Nucleic acid metabolism       | 7.47E-2 | 2          |
| Cell signalling               | 6.62E-2 | 3          |
| Small molecule biochemistry   | 7.47E-2 | 2          |
| Cell growth and proliferation | 7.47E-2 | 2          |
| Cell morphology               | 7.47E-2 | 2          |
| Top-10 functions associated with downregulated genes in OSCC-derived cell lines |         |            |
| Cellular movement b           | 1.60E-3 | 33         |
| Cell signalling               | 8.53E-3 | 31         |
| Cellular function and maintenance | 1.52E-11 to 31 |
| Small molecule biochemistry   | 8.53E-3 | 20         |
| Vitamin and mineral metabolism | 1.52E-11 to 32 |
| Tissue morphology             | 7.02E-3 | 33         |
| Molecular transport           | 8.53E-3 | 31         |
| Skeletal and vascular system development and function | 2.08E-10 to 33 |
| Cancer                        | 8.53E-3 | 27         |
| Cell-to-cell signalling and interaction | 1.01E-8 to 26 |

aNumber of associated genes. b Apoptosis, cell movement, proliferation, cell cycle progression, migration, binding quantity of cancer cell line. c Chemotaxis, migration, cell movement, mobilisation of haematologic cyte.
to intracellular Ca\(^{2+}\) homeostasis, suggesting that genes associated with cell signalling may act in a different manner during development of OSCC.

Among genes mapped to the network with the highest significance, *Grp94* was analysed further.

**GRP94 expression in OSCCs**

The state of Grp94 protein expression in six OSCC-derived cell lines (HSC-2, HSC-3, H-1, Sa-3, Ca9-22, and OK-92) \((n = 6)\) was evaluated by Western blot analysis. Figure 2A shows representative results. The band size was found to be 94 kDa as a single band, as reported by Little et al (1994). A significant \((P < 0.001)\) overexpression of Grp94 protein was observed in all OSCC-derived cell lines compared with normal oral epithelium. We also assessed the level of Grp94 protein expression in an OSCC-derived cell line (HSC-3) and HNOKs by immunofluorescence analysis. Representative cases of immunofluorescence are shown in Figure 2B. Strong immunoreactivity of Grp94 protein was detected in the cytoplasm of the OSCC-derived cell line HSC-3 compared with the HNOKs.

Immunohistochemical staining was performed using a series of surgical OSCC specimens, including 80 OSCCs with corresponding normal tissues and 20 OPLs. Grp94 overexpression was found not only in OSCCs \((P < 0.001)\) but also in OPLs \((P < 0.001)\). Among the OSCCs, 46 had significantly increased expression of Grp94 (immunohistochemical staining score, >65.56). In contrast, the normal tissues had no or significant downregulation of Grp94 expression and were considered Grp94 negative (Fisher’s exact test). There was no significant difference between the frequency of Grp94-positive cases and clinicopathologic features (Table 4).

Thirteen of 20 (65%) OPLs were defined as Grp94 positive. The Grp94-immunohistochemical staining scores for normal tissues, OPLs, and OSCCs, respectively, ranged from 0 to 65 (mean, 12.173), 12 to 191 (mean, 85.27), and 0 to 262 (mean, 106.511).

**Figure 2** Representative results of expression of Grp94 protein in oral squamous cell carcinomas (OSCC)-derived cell lines. (A) Western blot analysis of Grp94 protein in OSCC-derived cell lines and normal oral epithelium. All OSCC-derived cell line extracts exhibit a single band for Grp94 protein expression at high levels. In contrast, normal oral epithelium shows a low level of Grp94 protein expression. (B) Immunocytochemical analysis shows strong immunoreactivity of Grp94 in an OSCC-derived cell line (HSC-3) compared with human normal oral keratinocytes (HNOKs). DAPI staining was used to stain DNA. Bar, 100 \(\mu\)m. (C) Immunohistochemical staining of Grp94 in normal tissue, oral premalignant lesion (OPL), and primary OSCC. (a) Normal oral tissue exhibits negative Grp94 protein expression. (b) Grp94-negative case of OSCC. (c) Grp94-positive case of OPL. The immunoreaction is enhanced in the spinous layer. (d) Grp94-positive case of OSCC. Strong positive immunoreactivity for Grp94 is detected in the cytoplasm.
Grp94 expression levels in primary OSCCs and OPLs were significantly \((P < 0.001)\) higher than those in normal oral tissues (Figure 3). In contrast, we found no significant \((P = 0.448334)\) difference in Grp94-immunohistochemical staining scores between OSCCs and OPLs.

Grp94 mRNA expression levels were significantly upregulated in primary tumours of randomly selected Grp94-positive cases \((n = 29)\) compared to selected Grp94-negative cases \((n = 21, \text{Mann–Whitney U-test}, P < 0.001; \text{Figure 4A})\). mRNA expression levels were normalised to \(\text{GAPDH}\). The relative mRNA expression levels in positive and negative cases ranged from 113 to 297 (mean, 191.3) and 9 to 88 (mean, 56.6), respectively. Grp94 expression was upregulated significantly in all OSCC cell lines examined compared to normal oral epithelium used as a control (Figure 4B).

### Prognostic significance of GRP94 expression in OSCCs

To assess whether Grp94 expression also had a prognostic impact on patients with OSCC, clinical postoperative data from patients

| Clinical classification | Total | Grp94 (–) | Grp94 (+) | \(P\)-value\(^a\) |
|-------------------------|-------|-----------|-----------|----------------|
| Age at surgery (years)  |       |           |           |                |
| <60                     | 23    | 8 (30)    | 15 (70)   | 0.431974       |
| 60 ≤, < 70              | 26    | 11 (42)   | 15 (58)   |                |
| 70 ≤                   | 31    | 15 (48)   | 16 (52)   |                |
| Gender                  |       |           |           |                |
| Male                    | 33    | 13 (39)   | 20 (61)   | 0.654387       |
| Female                  | 47    | 21 (45)   | 26 (55)   |                |
| T-primary tumour        |       |           |           |                |
| T1                      | 5     | 2 (40)    | 3 (60)    | 0.55542        |
| T2                      | 35    | 15 (43)   | 20 (57)   |                |
| T3                      | 17    | 5 (29)    | 12 (71)   |                |
| T4                      | 23    | 12 (52)   | 11 (48)   |                |
| N-regional lymph node   |       |           |           |                |
| N(–)                    | 52    | 23 (44)   | 29 (56)   | 0.813185       |
| N(+)                    | 28    | 11 (39)   | 17 (61)   |                |
| Stage                   |       |           |           |                |
| I                       | 5     | 2 (40)    | 3 (60)    | 0.431974       |
| II                      | 16    | 7 (44)    | 9 (56)    | 0.756529       |
| III                     | 17    | 7 (41)    | 10 (59)   |                |
| IV                      | 52    | 28 (54)   | 24 (46)   |                |
| Histopathologic type    |       |           |           |                |
| Well differentiated      | 51    | 24 (47)   | 27 (53)   | 0.300615       |
| Moderately differentiated| 22    | 9 (41)    | 13 (59)   |                |
| Poorly differentiated    | 7     | 1 (14)    | 6 (86)    |                |
| Tumour site             |       |           |           |                |
| Tongue                  | 34    | 12 (35)   | 22 (65)   | 0.90283        |
| Gingiva                 | 29    | 13 (45)   | 16 (55)   |                |
| Oral floor              | 7     | 3 (43)    | 4 (57)    |                |
| Buccal mucosa           | 6     | 3 (50)    | 3 (50)    |                |
| Oropharynx              | 3     | 2 (67)    | 1 (33)    |                |
| Lip                     | 1     | 0 (0)     | 1 (100)   |                |
| Leukoplakia             | 20    | 7 (35)    | 13 (65)   |                |

\(^a\)\(P < 0.05\) was considered significant.

![Figure 3](image1.png) State of Grp94 protein expression in normal tissues \((n = 80)\), oral premalignant lesions \((\text{OPLs}) (n = 20)\) and primary oral squamous cell carcinomas \((\text{OSCCs}) (n = 80)\). Grp94 protein expression in OPLs and OSCCs is significantly higher than in normal oral tissues \((P < 0.001, \text{Mann–Whitney U-test})\). The results are expressed as the mean \(\pm\) s.d.

![Figure 4](image2.png) Grp94 mRNA expression status in primary oral squamous cell carcinomas \((\text{OSCCs})\) and OSCC-derived cell lines. \((\text{A})\) Comparison of Grp94 mRNA expression levels between Grp94-positive and Grp94-negative cases classified by immunohistochemical analysis. There is a significant difference in the Grp94 mRNA expression levels between the negative and positive cases \((P < 0.001, \text{Mann–Whitney’s U-test})\). \((\text{B})\) Quantification of mRNA levels in OSCC-derived cell lines by \(\text{qRT–PCR}\) analysis. Significant upregulation of Grp94 mRNA expression is seen in all OSCC-derived cell lines examined compared to normal oral epithelium. Data are expressed as the means \(\pm\) s.d.

**Figure 2C**. Grp94 expression levels in primary OSCCs and OPLs were significantly \((P < 0.001)\) higher than those in normal oral tissues (Figure 3). In contrast, we found no significant \((P = 0.448334)\) difference in Grp94-immunohistochemical staining scores between OSCCs and OPLs.

Grp94 mRNA expression levels were significantly upregulated in primary tumours of randomly selected Grp94-positive cases \((n = 29)\) compared to selected Grp94-negative cases \((n = 21, \text{Mann–Whitney U-test}, P < 0.001; \text{Figure 4A})\). mRNA expression levels were normalised to \(\text{GAPDH}\). The relative mRNA expression levels in positive and negative cases ranged from 113 to 297 (mean, 191.3) and 9 to 88 (mean, 56.6), respectively. Grp94 expression was upregulated significantly in all OSCC cell lines examined compared to normal oral epithelium used as a control (Figure 4B).

**Prognostic significance of GRP94 expression in OSCCs**

To assess whether Grp94 expression also had a prognostic impact on patients with OSCC, clinical postoperative data from patients...
whose tissue samples were investigated for Grp94 protein expression by immunohistochemical analysis were statistically analysed. Tumours with significantly increased expression levels of Grp94 protein (immunohistochemical staining score, \(>65.56\); maximum score of normal tissues) were defined as Grp94 positive \((n=46)\). Cases with no or significant downregulation of Grp94 protein expression (immunohistochemical staining score, \(<65.56\)) were considered Grp94 negative \((n=34)\).

Survival curves in relation to Grp94 protein expression are shown in Figure 5. Log-rank survival analysis indicated that Grp94-positive expression was significant both for disease-free survival \((P=0.011;\) Figure 5A\) and overall survival \((P=0.024;\) Figure 5B\), which suggested that high expression of Grp94 protein in patients with OSCCs was significantly associated with a poor prognosis.

**DISCUSSION**

Using a microarray technique, we identified a total of 100 \(\text{Ca}^{2+}\)-binding protein genes aberrantly expressed in OSCC cells. Pathway analysis could further characterise six networks from the 100 genes (Table 1). In addition, the network of the highest significance was generated entirely from 35 of the 100 focus genes (Figure 1), including a number of the \(\text{CCL}\) and \(\text{CXC}\) families. Previous studies have shown that chemokine-mediated JAK/STAT activation is critical for phospholipase C-\(\beta\) dependent \(\text{Ca}^{2+}\) flux (Li et al., 2000; Lewis, 2001; Thelen, 2001; Soriano et al., 2003). This evidence together with the current results suggests that reduced expression of the main chemokine families, \(\text{CCL}\) and \(\text{CXC}\), disrupts intracellular \(\text{Ca}^{2+}\) homeostasis and initiates oral tumorigenesis. The network with the highest significance also contained several cancer-related genes with high expression levels, including \(\text{DSG2}\), \(\text{PRKCA}\), \(\text{PLA2G10}\), and Grp94.

Considerable evidence has shown a significant association between the heat-shock protein 90 (Hsp90) and a wide range of human malignancies, including head and neck cancers (Ito et al., 1998; Baker et al., 2005; Yin et al., 2005). Grp94, also known as gp96, is the ER-resident member of the Hsp90 family constitutively expressed in virtually all cell types (Van et al., 1989) and the most abundant ER chaperon protein showing high homology (50%) to cytosolic counterpart Hsp90 (Sorger and Pelham, 1987). Increased expression of Grp94 both at the mRNA and protein levels also has been reported in several types of human cancers, such as oesophageal cancer (Wang et al., 2005b), lung cancer (Wang et al., 2005a), breast cancer (Gazit et al., 1999), liver cancer (Lim et al., 2005), and colon cancer (Wang et al., 2005c). We hypothesised that Grp94 also has potential as an emerging therapeutic target of interest for the treatment of oral cancer. However, the status of Grp94 in OSCC remains unclear and, therefore, we selected it for further investigation.

To confirm our hypothesis, we determined the protein/mRNA expression in a series of OSCC-derived cell lines and human primary OSCCs using immunofluorescence, Western blot analysis, qRT–PCR, and immunohistochemistry. Significant increases in Grp94-protein- and mRNA-expression levels were observed in the OSCC-derived cell lines examined compared with the normal oral epithelium. We also detected a comparatively strong tumour cell-localised cytoplasmic Grp94-immunoreaction in primary OSCCs. By evaluating the Grp94 immunohistochemistry scores, significant upregulation was evident in the primary OSCCs compared with normal tissues. While we could not find a significant correlation between Grp94 protein expression status and any clinicopathologic features examined, high levels of Grp94 protein expression was detected even in the OPLs examined. In addition, the current study showed that Grp94 overexpression is closely related to the disease-free/overall survival \((P=0.011\) and 0.024, respectively). Thus, we suggest that Grp94 could be associated with not only early-stage OSCC development but also tumour prognosis.

Interestingly, a recent study has shown that inhibition of Grp94 expression by geldanamycin in chronic lymphocytic leukaemia cells induces apoptosis with modest cytotoxic effects of
primary haematopoietic progenitors from normal bone marrow (Jones et al., 2004). In addition, targeting cancer cells with an antisense or RNAi procedure against Grp94 has shown increased chemosensitivity or radioresistance (Reddy et al., 1999; Kubota et al., 2005). From the therapeutic standpoint, this evidence may provide a novel/effective approach for treating human OSCCs.

In summary, we found novel specific networks of Ca$^{2+}$-binding protein genes in OSCC cells and identified several candidate genes for molecular targeting, especially for Grp94. Our findings may contribute to an understanding of key biologic functions and pathways of certain Ca$^{2+}$-binding protein genes associated with OSCC and should stimulate further investigation into Ca$^{2+}$-binding protein genes relevant to oral carcinogenesis.

ACKNOWLEDGEMENTS

We thank Lynda C Charters for editing this article. This study was partly supported by a Grant-in-Aid Scientific Research (no. 16591820) from the Ministry of Education, Culture, Science, and Technology of Japan.

REFERENCES

Baker H, Patel V, Molinolo AA, Shillitoe EJ, Enslie JF, Yoo GH, Meneses-Garcia A, Myers JN, El-Naggar AK, Gutkind JS, Hancock WS (2005) Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. *Oral Oncol* 41: 183 – 199

Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* 1: 11 – 21

Bustin SA, Li SR, Dorudi S (2001) Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer. *DNA Cell Biol* 20: 331 – 338

Chen D, Davies MP, Rudland PS, Barracough R (1997) Transcriptional down-regulation of the metastasis-inducing S100A4 (p92A) in benign but not in malignant rat mammary epithelial cells by GC-factor. *J Biol Chem* 272: 20283 – 20290

Ding Y, Robbins J, Fraser SP, Grimes JA, Djamgoz MB (2006) Comparative studies of intracellular Ca$^{2+}$ in strongly and weakly metastatic rat prostate cancer cell lines. *Int J Biochem Cell Biol* 38: 366 – 375

Durham AC, Walton JM (1982) Calcium ions and the control of proliferation in normal and cancer cells. *Biosci Rep* 2: 15 – 30

Endo Y, Uzawa K, Mochida Y, Shiba M, Bukawa H, Yokoe H, Tanzawa H (2004) Sarcoendoplasmic reticulum Ca2+(+)-ATPase type 2 down-regulated in human oral squamous cell carcinoma. *Int J Cancer* 116b: 225 – 231

Gazit G, Li J, Lee AS (1999) De-regulation of GRP stress protein expression in human breast cancer cell lines. *Breast Cancer Res Treat* 2: 135 – 146

Haaseleer F, Sokal I, Verlinden CLMJ, Erdjumnet-Bromage H, Tempst P, Pronin AN (2000) Ca (2+)-binding proteins in the retina: structure, function, and the etiology of human visual diseases. *J Biol Chem* 275: 1247 – 1260

Higo M, Uzawa K, Kawata T, Kato Y, Kouzu Y, Yamamoto N, Shibahara T, Mizoe JE, Ito H, Tsujii H, Tanzawa H (2006) Enhancement of SPHK1 gene encoding a novel member of the S100 family. *Int J Radiat Oncol Biol Phys* 65: 867 – 875

Huang JK, Huang CJ, Chen WC, Liu SI, Hsu SS, Chang HT, Tseng LL, Chou CT, Chang CH, Jan CR (2005) Independent [Ca$^{2+}$]$^{2+}$ increases and cell proliferation induced by the carcinogen safrole in human oral cancer cells. *Naunyn Schmiedebergs Arch Pharmacol* 372: 88 – 94

Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S, Nakao A (2005) S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. *Anticancer Res* 25: 1247 – 1250

Ishigani T, Uzawa K, Higo M, Nomura H, Saito K, Kato Y, Nakashima D, Shiba M, Bukawa H, Yokoe H, Kawata T, Ito H, Tanzawa H (2007) Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells. *J Cell Sci* 25: 1247 – 1250

Ito T, Kawabe R, Kurasono Y, Hara M, Kitamura H, Fujita K, Kanisawa M (1998) Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. *J Oral Pathol Med* 1: 18 – 22

Jones H, Uzawa K, Onda T, Kato Y, Saito K, Nakashima D, Ogawara K, Bukawa H, Yokoe H, Tanzawa H (2006) Down-regulation of 1D-myo-inositol 1,4,5-trisphosphate 3-kinase A protein expression in oral squamous cell carcinoma. *Int J Oncol* 28: 873 – 881

Koch G, Smith M, Macer D, Webster P, Mortara R (1986) Endoplasmic reticulum contains a common, abundant calcium-binding glycoprotein, endoplasm. *J Cell Biol* 86: 217 – 232

Kubota H, Suzuki T, Liu J, Takahashi S, Sugita K, Sekiya S, Suzuki N (2005) Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. *Int J Radiat Biol* 81: 701 – 709

Kunzelmann K (2005) Ion channels and cancer. *J Membr Biol* 205: 159 – 173

Lakshmikuttyamma A, Selvakumar P, Kanthan R, Kanthan SC, Sharma RK (2004) Overexpression of m-calpain in human colorectal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 13: 1604 – 1609

Lewis RS (2001) Calcium signaling mechanisms in T lymphocytes. *Annu Rev Immunol* 19: 497 – 521

Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D (2000) Roles of PLC-2 and -3 and the PI3K in chemotaxant-mediated signal transduction. *Science* 287: 1046 – 1049

Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Jung GH, Park CK (2005) Expression of heat shock proteins (HSP27, HSP60, HSP70, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. *Int J Oncol* 26: 2072 – 2079

Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS (1994) The glucose-regulated proteins (GRP78 and GRP94); functions, gene regulation, and applications. *Crit Rev Eukaryot Gene Expr* 4: 1 – 18

Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Sasaki T, Yamamoto E (2004) Correlation of S100A4 expression with invasion and metastasis in oral squamous cell carcinoma. *Oral Oncol* 40: 496 – 500

Nelson MR, Chazin WJ (1998) Calmodulin and Signal Transduction. *Academic Press: London*

Pietas A, Schluns K, Marenholz I, Schafer BW, Heizmann CW, Petersen I (2002) Molecular cloning and characterization of the human S100A4 gene encoding a novel member of the S100 family. *Genomics* 79: 513 – 522

Reddy RK, Lu J, Lee AS (1999) The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. *J Biol Chem* 274: 28476 – 28483

Saito K, Uzawa K, Endo Y, Kato Y, Nakashima D, Ogawara K, Shiba M, Bukawa H, Yokoe H, Tanzawa H (2006) Plasma membrane Ca2+-ATPase isoform 1 down-regulated in human oral cancer. *Oral Oncol* 41: 49 – 55

Saito K, Takazawa H, Uzawa K, Tanzawa H, Sato K (1998) Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5’ CpG island. *Int J Oncol* 12: 293 – 298

Shimada K, Uzawa K, Kato M, Endo Y, Shiba M, Bukawa H, Yokoe H, Seki N, Tanzawa H (2005) Aberrant expression of RB1 in human tongue cancer. *Br J Cancer* 92: 1915 – 1921

Sorger PK, Pelham HRB (1987) The glucose-regulated protein grp78 is related to heat shock protein hsp90. *J Mol Biol* 2: 341 – 344

Soriano SF, Serrano A, Fernandez-Falcon P, Martin de Ana A, Monterrubio M, Martinez C, Rodriguez-Frade JM, Mellado M (2003) Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses. *Eur J Immunol* 33: 1328 – 1333

Takahashi K, Kanazawa Y, Akiyama Y, Tazaki S, Takahara M, Muto T, Sato K (1989) Establishment and characterization of a cell line (SAS) from
poorly differentiated human squamous-cell carcinoma of the tongue. Jpn Stomatol Soc 38: 20–28
Takenaga K, Nakamura Y, Sakiyama S (1997) Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 14: 331–337
Thebault S, Flourakis M, Vanoverbergh K, Vandermoere F, Roudbaraki M, Lehen’kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL, Mauroy B, Shuba Y, Capiod T, Skrymny R, Prevarskaya N (2006) Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66: 2038–2047
Thelen M (2001) Dancing to the tune of chemokines. Nat Immunol 12: 129–134
Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC, Chang MT, Wu LW (2005) S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol 41: 349–357
Van Ginkel PR, Gee RL, Walker TM, Hu D-N, Heizmann CW, Polans AS (1998) The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448: 290–297
Van PN, Peter F, Soling HD (1989) Four intracisternal calcium-binding glycoproteins from rat liver microsomes with high affinity for calcium. No indication for calsequestrin-like proteins in inositol 1,4,5-trisphosphate-sensitive calcium sequestering rat liver vesicles. J Biol Chem 264: 17494–17501
Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, Wang L, Wang S, Chen Y (2005a) Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev 6: 544–551
Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y (2005b) Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J Gastroenterol 11: 429–432
Wang XP, Qiu FR, Liu GZ, Chen RF (2005c) Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 7: 1056–1059
Yin X, Zhang H, Burrows F, Zhang L, Shores CG (2005) Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 10: 3889–3896